Autolus Therapeutics (NASDAQ:AUTL) Posts Quarterly Earnings Results

Autolus Therapeutics (NASDAQ:AUTL) posted its quarterly earnings results on Tuesday. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10), Zacks reports. During the same period last year, the company earned ($0.26) earnings per share.

Autolus Therapeutics Stock Down 8.5 %

Shares of NASDAQ AUTL opened at $3.01 on Friday. Autolus Therapeutics has a 12-month low of $2.98 and a 12-month high of $7.45. The stock’s fifty day simple moving average is $3.92 and its two-hundred day simple moving average is $3.99. The stock has a market capitalization of $800.94 million, a PE ratio of -2.49 and a beta of 2.04. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.09.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Autolus Therapeutics in a research note on Monday.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.